Astrana Health's Earnings Growth Potential Through RAF Score Enhancement: A Buy Rating Analysis
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Baird Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $67
Astrana Health Analyst Ratings
Astrana Health Price Target Raised to $59.00/Share From $50.00 by Truist Securities
Astrana Health Analyst Ratings
Truist Securities Raises Price Target on Astrana Health to $59 From $50, Maintains Buy Rating
Astrana Health's Strong Q2 Performance and Strategic Growth Fuel Buy Rating
Astrana Health Analyst Ratings
Stifel Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $60
Jefferies Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $62
Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Astrana Health (ASTH)
Lake Street Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and REPRO-MED Systems (KRMD)
Astrana Health Analyst Ratings
Astrana Health (ASTH) Gets a Buy From Lake Street
Astrana Health Analyst Ratings
Astrana Health Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Astrana Health (ASTH)
No Data